Vor Biopharma Inc. 8-K

What Happened

• On June 8, 2026, Vor Biopharma Inc. announced that RemeGen Co., Ltd. received conditional approval from China’s National Medicinal Products Administration (NMPA) for telitacicept to treat adult patients with IgA nephropathy, and NMPA approval for telitacicept to treat adult patients with Sjögren’s disease. Vor furnished press releases as Exhibits 99.1 and 99.2 in the Form 8-K.

Key Details

• Date filed: June 8, 2026 (Current Report on Form 8-K, Item 7.01 Regulation FD Disclosure).
• Approvals: NMPA conditional approval for telitacicept for adult IgA nephropathy; NMPA approval for telitacicept for adult Sjögren’s disease.
• Announcements furnished as Exhibits 99.1 and 99.2; the information is furnished (not “filed”) under the Exchange Act and not incorporated by reference in other filings unless expressly stated.

Why It Matters

• These regulatory decisions are material milestones for telitacicept in China, a large pharmaceutical market; they represent progress toward commercialization of the drug in two indications.
• For investors, the approvals may affect the commercial outlook and value of programs tied to telitacicept and any related partnerships, but the filing does not disclose financial terms, revenue impact, or changes to Vor’s financial results or management.